口服阿苯达唑治疗弥漫性单侧亚急性神经视网膜炎患者的临床特征及预后
Clinical features and outcomes of patients with diffuse unilateral subacute neuroretinitis treated with oral albendazole.
作者信息
Souza Eduardo C, Casella Antônio Marcelo B, Nakashima Yoshitaka, Monteiro Mário Luiz R
机构信息
Department of Ophthalmology, Federal University of São Paulo (UNIFESP), Av. Angélica 1757 conj. 51, CEP 01227-200 São Paulo, Brazil.
出版信息
Am J Ophthalmol. 2005 Sep;140(3):437-445. doi: 10.1016/j.ajo.2005.03.065.
PURPOSE
To investigate the clinical features, visual function outcomes, and adverse events in patients with diffuse unilateral subacute neuroretinitis (DUSN) treated with high-dose oral albendazole.
DESIGN
Interventional case series.
METHODS
Twelve Brazilian patients, aged 7 through 36 years, with active DUSN in the early or late clinical stage, were recruited for this study between 1999 and 2001. A small variant motile worm was found in 4 (33.3%) of these cases. All patients were treated exclusively with high-dose oral albendazole (400 mg/d) for 30 days.
RESULTS
Improvement of visual acuity, visual field, and active ocular inflammatory signs was observed in all patients after 4 weeks of treatment (median follow-up: 3 years). Also, during the first weeks of treatment, evidence of worm inactivation was documented for the four patients with visible worms. No adverse drug side effects were observed in any of our cases during follow-up.
CONCLUSION
High-dose oral albendazole seems to be safe and beneficial for patients with DUSN.
目的
研究接受高剂量口服阿苯达唑治疗的弥漫性单侧亚急性神经视网膜炎（DUSN）患者的临床特征、视觉功能转归及不良事件。
设计
干预性病例系列研究。
方法
1999年至2001年期间，招募了12例年龄在7至36岁之间、处于临床早期或晚期活动期DUSN的巴西患者。其中4例（33.3%）发现有小型活动蠕虫变体。所有患者均仅接受高剂量口服阿苯达唑（400mg/d）治疗30天。
结果
治疗4周后（中位随访时间：3年），所有患者的视力、视野及眼部活动炎症体征均有改善。此外，在治疗的最初几周，4例发现可见蠕虫的患者有蠕虫失活的证据。随访期间，我们的任何病例均未观察到药物不良反应。
结论
高剂量口服阿苯达唑对DUSN患者似乎安全且有益。
Zotero 插件